A recent GAO report compares direct purchase prices paid by the Department of Defense (DOD) and the Department of Veterans Affairs (VA) for a sample of 43 brand-name and 40 generic drugs for the first quarter of 2012. In short, the GAO found that each agency obtained better prices on the type of drugs its beneficiaries use more, with generic drugs accounting for 83% of VA’s utilization of the sample drugs, and brand-name drugs accounting for 54% of DOD’s utilization. For instance, DOD’s average unit price for the 40 generic drugs was 66.6% higher than the VA’s average price, while the VA’s average unit price for the 43 brand-name drugs was 136.9% higher than DOD’s average price. The GAO points out that different pricing can result from factors such as variations in agency formulary design and prescription practices, differences in price and rebate negotiations with manufacturers, and differences in beneficiary populations.